Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of MVA-BN-WEV Vaccine in Healthy Adults
NCT04131595Phase 1Completed
- Sponsor
- Bavarian Nordic
- Start
- Oct 2019
- Primary completion
- Jul 2020
- Modality
- Viral Vector Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVA-BN WEV in Western equine encephalitis (WEE), eastern equine encephalitis (EEE) and Venezuelan equine encephalitis (VEE) (3 arms), sponsored by Bavarian Nordic. Primary endpoint: Serious Adverse Events at 7 months. Started Oct 2019; status: completed.
02
Drugs
MVA-BN WEV
03
Conditions
Western equine encephalitis (WEE)eastern equine encephalitis (EEE)Venezuelan equine encephalitis (VEE)
Beyond the preview
Go deeper on NCT04131595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131595.